Skip to content

Treatment Responses of Regimen Containing Clofazimine for M.avium complex Pulmonary Diseases

Treatment Responses of Regimen Containing Clofazimine for M.avium complex Pulmonary Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054533
Enrollment
Unknown
Registered
2021-12-19
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MAC Pulmonary Disease

Interventions

Experimental group:Drug sensitivity test of Clofazimine and Macrolide

Sponsors

Beijing Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years, gender is not limited; 2. Diagnosed with Mycobacterium avium complex lung disease; 3. Chest imaging examination found intrapulmonary lesions, with or without cavities; 4. The patient is not suitable for the standard MAC lung disease treatment regimen, including receiving anti-tuberculosis treatment in the past 3 years, using drugs that interact with rifampicin, and the standard regimen has a high risk of adverse reactions; 5. Women of childbearing age have a negative pregnancy urine test and agree to use high-efficiency contraceptive measures during the study; 6. Those who agree to participate in the trial and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Anti-MAC therapy has been started for more than 1 month before the visit; 2. Drug susceptibility test indicates macrolide resistance, or macrolide resistance gene mutation is found, or macrolide treatment for more than 6 months in the past 3 years; 3. Alanine aminotransferase exceeding 2 times the upper limit of normal or creatinine exceeding the upper limit of normal at the beginning of treatment; 4. Long-term use of immunosuppressants; 5. Those with other serious underlying diseases; 6. Lactation or pregnancy; 7. Karnofsky score <50; 8. According to the judgment of the research team, the subject suffers from any disease that is not suitable for participating in this subject or may prevent the patient from participating in the whole process of this subject; 9. Those who have a history of mental illness or those who fail the mental assessment.

Design outcomes

Primary

MeasureTime frame
Minimum inhibitory concentrations of clinical isolates of Mycobacterium avium complex;Clofazimine Cmax;Area under the curve of clofazimine plasma concentration from 0 hours to 8 hours;

Countries

China

Contacts

Public ContactDuan Hongfei

Beijing Chest Hospital

duanhongfei@hotmail.com+86 89509343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026